Neurocrine Biosciences
NBIX
574 hedge funds and large institutions have $10.7B invested in Neurocrine Biosciences in 2024 Q3 according to their latest regulatory filings, with 69 funds opening new positions, 237 increasing their positions, 202 reducing their positions, and 84 closing their positions.
25% more funds holding in top 10
Funds holding in top 10: 8 → 10 (+2)
17% more repeat investments, than reductions
Existing positions increased: 237 | Existing positions reduced: 202
7% more call options, than puts
Call options by funds: $79.4M | Put options by funds: $74M
0.9% less ownership
Funds ownership: 93.18% → 92.28% (-0.9%)
3% less funds holding
Funds holding: 594 → 574 (-20)
17% less capital invested
Capital invested by funds: $12.9B → $10.7B (-$2.17B)
18% less first-time investments, than exits
New positions opened: 69 | Existing positions closed: 84
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$140M |
| 2 |
DM
Deerfield Management
New York
|
+$85.8M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$85M |
| 4 |
State Street
Boston,
Massachusetts
|
+$74M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
+$49.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$119M |
| 2 |
AC
Armistice Capital
New York
|
-$109M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$81M |
| 4 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$74.5M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$66.7M |
NBIX Hedge Fund Activity: Q3 2024 in Review
574 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q3 2024, worth a combined $10.7B — down 17% from $12.9B a quarter earlier.
Sellers outnumbered buyers: 84 funds closed out of NBIX and 69 opened new positions — a net loss of 15 holders — while 202 trimmed existing stakes and 237 added.
The largest buyer was Citadel Advisors, adding an estimated $140M. The largest seller was JP Morgan Chase, cutting an estimated $119M.
- 574 institutional investors held Neurocrine Biosciences (NBIX) as of Q3 2024, down from 594 in Q2 2024.
- Funds reported $10.7B of Neurocrine Biosciences stock for Q3 2024, down 17% quarter-over-quarter.
- 69 funds opened new Neurocrine Biosciences positions in Q3 2024 and 84 closed out, a net change of -15 holders.
- The largest Neurocrine Biosciences buyer in Q3 2024 was Citadel Advisors, an estimated $140M added.
- The largest Neurocrine Biosciences seller in Q3 2024 was JP Morgan Chase, an estimated $119M sold.
Based on aggregated 13F filings for Q3 2024.